Drug
Tebentafusp
Tebentafusp: highest development phase Phase 3, developed by Immunocore. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Immunocore
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tebentafusp NCT06246149 | Phase 3 | Uveal Melanoma |
| Tebentafusp NCT05549297 | Phase 3 | Advanced Melanoma |
| Tebentafusp NCT05315258 | Phase 2 | Melanoma (Skin) |
| Tebentafusp NCT06627244 | Phase 2 | Metastatic Uveal Melanoma |
| Tebentafusp NCT06070012 | Phase 2 | Uveal Melanoma |
| Tebentafusp (IMCgp100) NCT02535078 | Phase 1/2 | Malignant Melanoma |
Latest
No recent events.
Follow Tebentafusp on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.